Key Precipitating Factors and Evidence‑Based Management of Heart‑Failure Decompensation

1. Patient‑Related Factors

• Medication non‑adherence is a major, preventable cause of HF hospital admission – identified in multiple Circulation analyses. 1
• Dietary sodium‑ and fluid‑restriction violations occur in roughly 52 % of decompensation episodes (Circulation cohort). 1
• Financial or other barriers to adherence should be actively screened (Circulation). 2

2. Cardiovascular Triggers

Hypertension

• Uncontrolled hypertension is a critical precipitant, especially in Black patients, women, and those with HFpEF (Circulation). 4
• ≈ 50 % of HF admissions in the ADHERE registry had BP > 140/90 mm Hg (Circulation). 1
• Abrupt discontinuation of antihypertensive therapy can trigger worsening HF (Circulation). 1

Arrhythmias

• Atrial fibrillation (AF) prevalence exceeds 30 % in acute HF (Circulation). 2
• Other tachyarrhythmias also contribute to decompensation (Circulation). 3

Acute Myocardial Ischemia

• Acute coronary syndromes precipitate HF decompensation and require urgent evaluation (Circulation 2013 & 2022). 5
• Patients with ischemia may need urgent revascularization (Circulation 2022). 5

3. Infectious Triggers

Respiratory Infections

• Respiratory infections are present in ≈ 28‑29 % of decompensation episodes (Circulation). 1
• They add hypoxia and metabolic stress, worsening outcomes (Circulation). 2

Other Infections

• Pneumonia and viral illnesses increase metabolic demand, contributing to decompensation (Circulation). 3
• Sepsis can cause reversible myocardial depression via cytokine release (Circulation). 2

4. Medication‑Induced Decompensation

Negative Inotropic Agents

• Recent initiation of calcium‑channel blockers (verapamil, nifedipine, diltiazem) can precipitate HF worsening (Circulation 2013; Canadian J Cardiol 2006). 6
• New or uptitrated β‑blockers may trigger decompensation (Circulation). 3
• Class IC antiarrhythmics (flecainide, propafenone, disopyramide) are associated with decompensation (Circulation; Canadian J Cardiol 2006). 6

Sodium‑Retaining Drugs

• NSAIDs and COX‑2 inhibitors (e.g., celecoxib) are major contributors to fluid overload (Circulation 2013; Canadian J Cardiol 2007). 7
• Systemic corticosteroids promote sodium retention and HF decompensation (Circulation; Canadian J Cardiol 2006). 6
• Thiazolidinediones (pioglitazone, rosiglitazone) cause fluid retention (Circulation; Canadian J Cardiol 2006). 6
• Over‑the‑counter decongestants such as pseudoephedrine can exacerbate HF (Circulation). 3

5. Renal Considerations

• Renal function decline both results from and drives HF decompensation (Circulation). 2
• A rise in serum creatinine of ~30 µmol/L during admission is linked to longer stay and higher early/late mortality (Canadian J Cardiol 2007). 8
• Adverse cardiovascular events increase when eGFR falls below 60 mL/min (Canadian J Cardiol 2007). 8
• Reversible renal insults include systemic hypotension, volume depletion, and nephrotoxic drugs (NSAIDs, ACE‑I/ARB, spironolactone in dehydration) (Canadian J Cardiol 2007). 9
• Urinary‑tract obstruction or infection also represents a reversible cause (Canadian J Cardiol 2007). 9

6. Endocrine & Metabolic Factors

• Correcting hyper‑ or hypothyroidism can reverse abnormal cardiovascular function (Circulation). 3
• In patients on amiodarone, thyroid dysfunction should be specifically evaluated (Circulation). 2

7. Other Cardiovascular Disorders

• Pulmonary embolism should be considered in HF patients due to a hypercoagulable state (Circulation). 1
• Valvular disease, endocarditis, myopericarditis, and aortic dissection are recognized precipitants (Circulation). 1

8. Substance Use

• Excessive alcohol intake contributes to HF decompensation (Circulation). 2
• Illicit stimulants (cocaine, methamphetamine) warrant investigation as potential triggers (Circulation). 3

9. Anemia

• Hemoglobin < 90‑110 g/L is associated with increased HF symptom burden (Canadian J Cardiol 2007). 10
• Anemia, often secondary to chronic disease or renal insufficiency, significantly worsens outcomes (Canadian J Cardiol 2007). 10

10. Hemodynamic Assessment

• Up to 25 % of patients exhibit disproportionate right‑ vs left‑sided filling‑pressure elevation, hindering effective decongestion (Circulation 2022; JACC 2019). 5
• Patients with a “cold‑and‑dry” phenotype may have hidden elevated filling pressures; invasive hemodynamic measurement is recommended (JACC 2019). 11
• Uncertainty about hemodynamic status correlates with poorer outcomes, underscoring need for invasive assessment (JACC 2019). 11

11. Management Strategies During Intercurrent Illness

• Temporarily hold spironolactone in acute dehydrating illness to reduce hyper‑kalemia risk (Canadian J Cardiol 2007). 10
• Daily review of diuretics, ACE‑I/ARB, and spironolactone is advised in oliguric, hemodynamically stable patients (Canadian J Cardiol 2007). 9
• Prompt measurement of electrolytes, BUN, and creatinine is essential even without overt volume overload or depletion (Canadian J Cardiol 2007). 10